BR0206433A - Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto - Google Patents
Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um compostoInfo
- Publication number
- BR0206433A BR0206433A BR0206433-2A BRPI0206433A BR0206433A BR 0206433 A BR0206433 A BR 0206433A BR PI0206433 A BRPI0206433 A BR PI0206433A BR 0206433 A BR0206433 A BR 0206433A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparing
- pharmaceutical composition
- compounds
- useful
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003892 ceramide glucosyltransferase inhibitor Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0100889.5 | 2001-01-12 | ||
GBGB0100889.5A GB0100889D0 (en) | 2001-01-12 | 2001-01-12 | Compounds |
PCT/GB2002/000106 WO2002055498A1 (en) | 2001-01-12 | 2002-01-11 | Pharmaceutically active piperidine derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
BR0206433A true BR0206433A (pt) | 2003-12-30 |
BRPI0206433B1 BRPI0206433B1 (pt) | 2020-01-07 |
BRPI0206433B8 BRPI0206433B8 (pt) | 2021-05-25 |
Family
ID=9906757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0206433-2 BRPI0206433B8 (pt) | 2001-01-12 | 2002-01-11 | composto, composição farmacêutica, e, uso de um composto |
Country Status (19)
Country | Link |
---|---|
US (3) | US20040097551A1 (pt) |
EP (1) | EP1362031B1 (pt) |
JP (1) | JP4313572B2 (pt) |
KR (1) | KR100879651B1 (pt) |
CN (1) | CN1267420C (pt) |
AT (1) | ATE389635T1 (pt) |
AU (1) | AU2002219363B2 (pt) |
BR (1) | BRPI0206433B8 (pt) |
CA (1) | CA2433675C (pt) |
DE (1) | DE60225671T2 (pt) |
ES (1) | ES2304439T3 (pt) |
GB (1) | GB0100889D0 (pt) |
HU (1) | HU229428B1 (pt) |
IL (1) | IL156873A0 (pt) |
MX (1) | MXPA03006185A (pt) |
PT (1) | PT1362031E (pt) |
RU (1) | RU2279425C2 (pt) |
WO (1) | WO2002055498A1 (pt) |
ZA (1) | ZA200305118B (pt) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0100889D0 (en) | 2001-01-12 | 2001-02-21 | Oxford Glycosciences Uk Ltd | Compounds |
WO2001097829A2 (en) * | 2000-06-19 | 2001-12-27 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
EP1524976B1 (en) * | 2002-03-13 | 2006-09-13 | Unither Pharmaceuticals, Inc. | A non-hormonal approach to male contraception |
JP4575156B2 (ja) * | 2002-07-17 | 2010-11-04 | アクテリオン ファーマシューティカルズ リミテッド | グルコシルセラミドシンターゼの阻害剤としてのピペリジントリオール誘導体 |
CA2492410C (en) | 2002-07-17 | 2011-09-13 | Oxford Glycosciences (Uk) Ltd | Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase |
GB0313677D0 (en) * | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compound |
GB0313678D0 (en) * | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compounds |
EP1528056A1 (en) * | 2003-10-29 | 2005-05-04 | Academisch Ziekenhuis bij de Universiteit van Amsterdam | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors |
DE602004030604D1 (de) * | 2003-10-29 | 2011-01-27 | Genzyme Corp | N-(5-adamantane-1-yl-methoxy-pentyl)desoxynojirimycin oder eines pharmazeutischen salzes davon zur verwendung bei der behandlung der insulinresistenz |
GB0400812D0 (en) * | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
US20060025449A1 (en) * | 2004-03-25 | 2006-02-02 | United Therapeutics | Use of N-substituted imino sugars for appetite suppression |
EP1797898A4 (en) * | 2004-09-08 | 2009-09-09 | Takeda Pharmaceutical | MEDICAMENT FOR THE PREVENTION / TREATMENT OF ARTERIOSCLEROSIS |
BRPI0517701A8 (pt) | 2004-11-10 | 2018-01-23 | Genzyme Corp | métodos de tratamento de diabetes mellitus |
US8716327B2 (en) | 2006-05-09 | 2014-05-06 | Genzyme Corporation | Methods of treating fatty liver disease |
EP2023927B1 (en) * | 2006-05-24 | 2015-02-25 | United Therapeutics Corporation | Deoxynojirimycin and d-arabinitol analogs and methods of using |
GB0614947D0 (en) * | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
US8097728B2 (en) * | 2007-04-30 | 2012-01-17 | Philadelphia Health & Education Corporation | Iminosugar compounds with antiflavirus activity |
EP2594563B1 (en) | 2007-05-31 | 2018-07-18 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
EP2209473B1 (en) * | 2007-10-05 | 2017-11-22 | Genzyme Corporation | Method of treating polycystic kidney diseases with ceramide derivatives |
CA2731685A1 (en) | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
EP3078373A1 (en) | 2008-10-03 | 2016-10-12 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitor |
EP2889043B1 (en) | 2008-12-16 | 2019-04-10 | Genzyme Corporation | Synthetic intermediates for preparing oligosaccharide-protein conjugates |
CA2753195C (en) | 2009-02-23 | 2015-06-02 | United Therapeutics Corporation | Iminosugars and methods of treating viral diseases |
KR20170117614A (ko) * | 2009-02-24 | 2017-10-23 | 유나이티드 세러퓨틱스 코오포레이션 | 이미노슈가 및 아레나바이러스성 감염을 치료하는 방법 |
EP2440205B1 (en) | 2009-06-12 | 2014-08-27 | United Therapeutics Corporation | Iminosugars for use in the treatment of bunyaviral and togaviral diseases |
US20110065753A1 (en) * | 2009-09-04 | 2011-03-17 | United Therapeutics Corporation | Methods of treating poxviral infections |
US20110065752A1 (en) * | 2009-09-04 | 2011-03-17 | United Therapeutics Corporation | Methods of treating orthomyxoviral infections |
EP2473046B1 (en) * | 2009-09-04 | 2014-10-22 | United Therapeutics Corporation | Iminosugars for their use in the treatment of filoviral diseases |
US20110136868A1 (en) * | 2009-12-07 | 2011-06-09 | University Of Oxford | Agents for inhibiting osteoclastogenesis and/or osteoclast activation |
ES2371398B1 (es) * | 2010-06-04 | 2013-05-20 | Bioglane, S.L.N.E. | Uso de un iminoazúcar como inhibidor de la adherencia a células epiteliales. |
EP2394667A1 (en) * | 2010-06-10 | 2011-12-14 | Laboratorios Del Dr. Esteve, S.A. | Vectors and sequences for the treatment of diseases |
EP2785335B8 (en) | 2011-11-29 | 2017-08-02 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and pharmaceutical compositions for the treatment of darier disease |
EP2968300A4 (en) * | 2013-03-15 | 2016-09-28 | Unither Virology Llc | ANTIBACTERIAL COMPOUNDS |
JP2016517887A (ja) * | 2013-05-02 | 2016-06-20 | ザ チャンセラー,マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード | イミノ糖を使用した糖脂質阻害 |
TWI770184B (zh) | 2017-06-01 | 2022-07-11 | 瑞士商愛杜西亞製藥有限公司 | N-丁基脫氧半乳糖野尻黴素(N-butyldeoxygalactonojirimycin)之結晶型 |
WO2020193746A1 (en) | 2019-03-28 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival of patients suffering from melanoma |
JP2022531933A (ja) * | 2019-05-10 | 2022-07-12 | アレクトス セラピューティックス インコーポレイテッド | 非リソソームグルコシルセラミダーゼ阻害剤及びその使用 |
AU2021269232A1 (en) * | 2020-05-07 | 2022-12-08 | Alectos Therapeutics Inc. | Non-lysosomal glucosylceramidase inhibitors and uses thereof |
CR20220600A (es) * | 2020-05-07 | 2023-04-11 | Alectos Therapeutics Inc | Inhibidores de glucosilceramidasa no lisosomal y los usos de los mismos |
EP4201403A1 (en) | 2021-12-21 | 2023-06-28 | Som Innovation Biotech, S.L. | Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO154918C (no) * | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
DE3007078A1 (de) * | 1980-02-26 | 1981-09-10 | Bayer Ag, 5090 Leverkusen | Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung |
DE3024901A1 (de) | 1980-07-01 | 1982-01-28 | Bayer Ag, 5090 Leverkusen | Herbizide mittel auf basis von piperidin-derivaten |
DE3247615A1 (de) * | 1982-12-23 | 1984-07-05 | Hoechst Ag, 6230 Frankfurt | Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
DE3737523A1 (de) * | 1987-11-05 | 1989-05-18 | Bayer Ag | Verwendung von substituierten hydroxypiperidinen als antivirale mittel |
US5003072A (en) * | 1988-11-03 | 1991-03-26 | G. D. Searle & Co. | 1,5-dideoxy-1,5-imino-D-glucitol derivatives |
JPH02306962A (ja) | 1989-05-19 | 1990-12-20 | Meiji Seika Kaisha Ltd | 新規n―置換―1―デオキシノジリマイシン誘導体及びそれを含有する癌細胞転移抑制剤 |
JPH0324057A (ja) | 1989-06-22 | 1991-02-01 | Tosoh Corp | ポリヒドロキシピペリジン類及びその製造法 |
KR920703056A (ko) | 1989-09-07 | 1992-12-17 | 아만 히데아키 | 항 바이러스제 |
EP0536402A4 (en) | 1990-06-29 | 1993-05-12 | Nippon Shinyaku Company, Limited | Piperidine derivative |
US5276120A (en) * | 1991-05-30 | 1994-01-04 | The Scripps Research Institute | Process for forming omega-deuxy-azasugars |
US5916759A (en) | 1993-05-05 | 1999-06-29 | Boehringer Mannheim Gmbh | Cholesterol oxidase from Brevibacterium sterolicum |
US6291657B1 (en) * | 1993-05-13 | 2001-09-18 | Monsanto Company | Deoxygalactonojirimycin derivatives |
US5798366A (en) | 1993-05-13 | 1998-08-25 | Monsanto Company | Method for treatment of CNS-involved lysosomal storage diseases |
JP4564108B2 (ja) * | 1996-07-15 | 2010-10-20 | ジェンザイム コーポレーション | デオキシノジリマイシン誘導体及び該誘導体のグルコシルセラミダーゼ阻害剤としての用途 |
EP0983239A1 (en) * | 1997-05-06 | 2000-03-08 | Novo Nordisk A/S | Novel heterocyclic compounds |
AU8286998A (en) * | 1997-07-03 | 1999-01-25 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Genes for niemann-pick type c disease |
CA2309321A1 (en) * | 1997-11-10 | 1999-05-20 | G.D. Searle & Co. | Use of alkylated iminosugars to treat multidrug resistance |
US6610703B1 (en) | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
WO2000056334A1 (en) | 1999-03-19 | 2000-09-28 | The Trustees Of Boston College | Use of imino sugars for anti-tumor therapy |
GB9909064D0 (en) * | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
GB0100889D0 (en) | 2001-01-12 | 2001-02-21 | Oxford Glycosciences Uk Ltd | Compounds |
ATE234626T1 (de) * | 1999-07-26 | 2003-04-15 | Searle & Co | Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin mit glucocerebrosidase enzyme zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten |
AU1840101A (en) * | 1999-08-10 | 2001-03-05 | Chancellor, Masters And Scholars Of The University Of Oxford, The | Long chain n-alkyl compounds and oxo-derivatives thereof |
US7256005B2 (en) * | 1999-08-10 | 2007-08-14 | The Chancellor, Masters And Scholars Of The University Of Oxford | Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity |
EP1524976B1 (en) * | 2002-03-13 | 2006-09-13 | Unither Pharmaceuticals, Inc. | A non-hormonal approach to male contraception |
JP4575156B2 (ja) | 2002-07-17 | 2010-11-04 | アクテリオン ファーマシューティカルズ リミテッド | グルコシルセラミドシンターゼの阻害剤としてのピペリジントリオール誘導体 |
CA2492410C (en) * | 2002-07-17 | 2011-09-13 | Oxford Glycosciences (Uk) Ltd | Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase |
GB0313677D0 (en) | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compound |
GB0313678D0 (en) | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compounds |
GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
-
2001
- 2001-01-12 GB GBGB0100889.5A patent/GB0100889D0/en not_active Ceased
-
2002
- 2002-01-11 WO PCT/GB2002/000106 patent/WO2002055498A1/en active IP Right Grant
- 2002-01-11 IL IL15687302A patent/IL156873A0/xx active IP Right Grant
- 2002-01-11 BR BR0206433-2 patent/BRPI0206433B8/pt not_active IP Right Cessation
- 2002-01-11 RU RU2003124756/04A patent/RU2279425C2/ru active
- 2002-01-11 CA CA2433675A patent/CA2433675C/en not_active Expired - Lifetime
- 2002-01-11 PT PT02729458T patent/PT1362031E/pt unknown
- 2002-01-11 AU AU2002219363A patent/AU2002219363B2/en not_active Expired
- 2002-01-11 CN CNB028062264A patent/CN1267420C/zh not_active Expired - Lifetime
- 2002-01-11 DE DE60225671T patent/DE60225671T2/de not_active Expired - Lifetime
- 2002-01-11 JP JP2002556170A patent/JP4313572B2/ja not_active Expired - Lifetime
- 2002-01-11 ES ES02729458T patent/ES2304439T3/es not_active Expired - Lifetime
- 2002-01-11 AT AT02729458T patent/ATE389635T1/de active
- 2002-01-11 MX MXPA03006185A patent/MXPA03006185A/es active IP Right Grant
- 2002-01-11 KR KR1020037009309A patent/KR100879651B1/ko active IP Right Grant
- 2002-01-11 HU HU0303891A patent/HU229428B1/hu unknown
- 2002-01-11 EP EP02729458A patent/EP1362031B1/en not_active Expired - Lifetime
-
2003
- 2003-07-01 ZA ZA200305118A patent/ZA200305118B/en unknown
- 2003-07-11 US US10/618,165 patent/US20040097551A1/en not_active Abandoned
-
2005
- 2005-08-03 US US11/196,153 patent/US8729099B2/en not_active Expired - Lifetime
-
2014
- 2014-04-07 US US14/246,879 patent/US9199935B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
RU2279425C2 (ru) | 2006-07-10 |
CN1496351A (zh) | 2004-05-12 |
HU229428B1 (en) | 2013-12-30 |
ZA200305118B (en) | 2004-10-01 |
BRPI0206433B1 (pt) | 2020-01-07 |
RU2003124756A (ru) | 2005-01-10 |
PT1362031E (pt) | 2008-06-12 |
DE60225671T2 (de) | 2009-04-16 |
BRPI0206433B8 (pt) | 2021-05-25 |
US20040097551A1 (en) | 2004-05-20 |
IL156873A0 (en) | 2004-02-08 |
CA2433675C (en) | 2011-03-22 |
KR100879651B1 (ko) | 2009-01-20 |
HUP0303891A2 (hu) | 2004-03-29 |
EP1362031A1 (en) | 2003-11-19 |
HUP0303891A3 (en) | 2010-01-28 |
DE60225671D1 (de) | 2008-04-30 |
JP2004517869A (ja) | 2004-06-17 |
CA2433675A1 (en) | 2002-07-18 |
MXPA03006185A (es) | 2004-12-03 |
US20060074107A1 (en) | 2006-04-06 |
GB0100889D0 (en) | 2001-02-21 |
CN1267420C (zh) | 2006-08-02 |
EP1362031B1 (en) | 2008-03-19 |
US20140303208A1 (en) | 2014-10-09 |
KR20030081383A (ko) | 2003-10-17 |
JP4313572B2 (ja) | 2009-08-12 |
US9199935B2 (en) | 2015-12-01 |
US8729099B2 (en) | 2014-05-20 |
AU2002219363B2 (en) | 2007-11-01 |
WO2002055498A1 (en) | 2002-07-18 |
ES2304439T3 (es) | 2008-10-16 |
ATE389635T1 (de) | 2008-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0206433A (pt) | Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto | |
BRPI0506843A (pt) | composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto | |
DK1206467T3 (da) | N-heterocykliske derivater som NOS-inhibitorer | |
BR0314113A (pt) | Derivados de amino propanol | |
DK0968206T3 (da) | N-heterocykliske derivater som NOS-inhibitorer | |
BR0210464A (pt) | Composto, composição farmacêutica, processo para preparar um composto, e, uso de um composto | |
DK0931788T3 (da) | Metalloproteasehæmmere | |
ECSP055671A (es) | Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa | |
NO20054787D0 (no) | Indenderivater som farmasotiske midler | |
BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
DK1268471T3 (da) | N-heterocykliske derivater som NOS-inhibitorer | |
BRPI0512986A (pt) | novos derivados de hidantoìna | |
BR0310077A (pt) | Novos compostos e sua utilização | |
BRPI0517033A (pt) | novos derivados de hidantoìna como inibidores de metaloproteinase | |
BRPI0411308A8 (pt) | Composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto | |
UY28528A1 (es) | Nuevos compuestos | |
SE0403085D0 (sv) | Novel componds | |
BRPI0108990B8 (pt) | processo para preparação de derivados de pirimidona com atividade antifungos | |
BR9807988A (pt) | Processo para a preparação de um composto, e, composto. | |
BR9911250A (pt) | Processo para preparação de compostos | |
BRPI0415034A (pt) | derivados de aminopiridina como inibidores de não-sintase induzìveis | |
BR0113259A (pt) | Processo para a preparação de um composto, composto e processo para a preparação de compostos | |
BR0308601A (pt) | inibidores de carboxipeptidase b de plasma | |
BR0009453A (pt) | Processo para a preparação de um composto | |
BRPI0417263A (pt) | imidazopiridinas para uso como inibidores de secreção gástrica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVER Free format text: TRANSFERIDO DE: OXFORD GLYCOSCIENCES (UK) LIMITED |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B25C | Requirement related to requested transfer of rights |
Owner name: THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVER Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870180063890 DE 24/07/2018, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DA EMPRESA TITULAR DO PEDIDO ?ACTELION PHARMACEUTICALS LIMITED? E O NOME DA EMPRESA CEDENTE ?ACTELION PHARMACEUTICALS LTD?. Owner name: THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITH OF OXFORD (GB) ; ACTELION PHARMACEUTICALS LIMITED (CH) Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870180063890 DE 24/07/2018, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DA EMPRESA TITULAR DO PEDIDO ?ACTELION PHARMACEUTICALS LIMITED? E O NOME DA EMPRESA CEDENTE ?ACTELION PHARMACEUTICALS LTD?. |
|
B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVER Free format text: ANULADA A PUBLICACAO CODIGO 25.3 NA RPI NO 2487 DE 04/09/2018 POR TER SIDO INDEVIDA. |
|
B25A | Requested transfer of rights approved |
Owner name: THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVER |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/01/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/01/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 11/01/2022 |